Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I see petie is posting under his own name now.
great job pete, you put the company in such a dismal rut it cannot climb out of.
5 years as ceo millions of shareholder dollars in your pocket and yet you found away too drop the share price 1.50 lower than when you where given the golden ticket.
pete deserves a cabinet position in the biden administration
My name says it all. How can SEC not see the BS co and do something. Insidwr selling at top on fake rumor?? So much more.
Well so much for yesterday. Following market today.
Well, Auphie up today whilst most bios are down. If news, of course we are last to know. Is it anticipation of something or just shorts getting fatigued?
You're only late by about 8 months buddy. See where you are spamming other boards as well telling them what price the stock is under.
Yea, Pete’s not the wonder boy we all hoped he would be, I would agree that his negotiation skills are pretty thin, after all the excitement around AUPH , he let the water get cool down. I brought up your family because you post about them often, so you may want to post with a little less emotion and more forethought. I just can’t believe your still here and holding, remember, always believe in a stock or you’ll get flushed everytime you hear news, or a tip.Id say now is a great time to double down
thanks for keeping track of my family. with a useless ceo that takes a huge check without working for it and sells off stock he didn't pay for.
even with easter coming up, even God cannot resurrect this stock after what pete has done to it. only people worth less than pete is those who keep voting him in. a win for pete is a loss of shareholders and patients. you know where you can roll your easter egg.
Cervelo, damn, you’re still here just holding your cards to your chest??
Are you going to start a fight with your brother at the Easter ?
The "2s", given increasing revenues and a stock buy-back, is a bit of lunge at this point. I can remember a few years ago when the stock traded at this level without an FDA approval.
Possible but unlikely. That would put market cap at 1.5x revenue which would be atomically undervalued.
As predicted $4’s
$2’s almost inevitable now.
Note- I only mentioned "trump" to keep cervelo calmer
cheers.
BEST POST OF THE MONTH, LOL!
Obviously FDA approval means nothing....
As long as pete is at the helm.
pettie better unload the other 2/3's of his holdings before the stock price becomes more worthless than he is. Amazing people voted to keep him in and give him a raise, almost 1.75 million a year for doing nothing, based on his incompetence if he is voted to stay on his salary will easily be elevated to over 5 million a year.
Where are the pettiepumpers hiding that always posted that we will not be around by next financials because this pig will be already bought out.
I would say we may not be around by next financials because pete may have destroyed this company to the point of no rteturn.
I understand his playbook has come from joe and barry
Great story!
Maybe no more dialysis in the future.
First heart valves now kidneys.
We must be closely related.
Guessing Greenleaf even more so.
cheers
What do you think will happen faster - Lupy becoming 1b dollar drug or dialysis obsolete?
https://www.nytimes.com/2024/03/21/health/pig-kidney-organ-transplant.html
Moose. its the FDA that matters ...not some PR from AUPH .
Prescribers will follow the FDA PDF ...if they don't they become liable
Kiwi
Doesn't this proof trump the black box?
LONG TERM PHASE 3 DATA PUBLISHED IN ARTHRITIS & RHEUMATOLOGY SHOWS LUPKYNIS® (VOCLOSPORIN) PRESERVED KIDNEY FUNCTION UP TO THREE YEARS IN LUPUS NEPHRITIS PATIENTS WITH NO NEW OR UNEXPECTED ADVERSE EVENTS
https://www.auriniapharma.com/investors-and-media/news-events/press-releases/detail/299/long-term-phase-3-data-published-in-arthritis
*Note- I only mentioned "trump" to keep cervelo calmer
cheers
What is the evidence it should be SOC ( standard of care ) ?
Prescribing PDF limits it use ...read the PDF .
Its a huge risk for the prescriber to prescribe this drug outside of the parameters ..including the monitoring requirements ,,,set forth in the PDF .
They won't do it .
Chk risk of hyperkalemia ...thats how many CKD patients die ...it sets of wild heart arrhythmias
Whatalane- why hasn't there been a label change?
You said "It has a boxed warning ...."
True enough.....but the evidence seems overwhelming that Lupkynis deserves to be SOC
Why hasn't this happened?
TIA
cheers
RMB Lupkynis can be a difficult drug to use . https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf
It has a boxed warning , not recommended for eGFR < 45 , some time demanding monitoring requirements plus warnings .
Because its an expensive Brand drug the push back from the insurers via prior authorization requisitions ( did your patient try and fail Benylsta ...please document etc or the generics ...etc ) creates huge paper work for Nephrologists and their PA's
The Nephrologist and their PA's are under an intense work load already and to fight thru all the paper work / prior authorization document , monitor the drugs affect etc is more then what most want to deal with unless its almost the last chance for their LN patient to prevent decline into need for dialysis.
My wife knows of only 2 patients on Lupkynis ...largely because of the issues mentioned above .
The Ceo , from an earlier post , seems to be bailing .
I doubt any BP is interested .
JMO
Good luck
Kiwi
Obviously Pete will be gone after this AGM
seems I have support in stating what a lousy manager pete is. and now hw starts selling all the fre stock he awarded himself making MILLIONS off the backs of shareholders. The stock is lower than when he became ceo and yet has stolen millions upon millions. I have always stated pete is only here for pete. so go ahead a slam me ye naysayers. admit you have been the fools and we have all lost money in what should have been a guaranteed winner for shareholders and the people who need the drug.
Moose, your last question is excellent and on point.
Your earlier commentary in the post can be explained by recognizing how our healthcare is strangled by monied interests, like insurers, PBM, etc. The other side that coin is that while Aurinia has enormous margins for Lupy, they apparently are not interested in dropping the price to entice more usage and/or better insurance coverage.
Those huge margins though, should entice BP no?
Hi RMB,
I have to admit I'm mystified by this situation with AUPH.
Last year was a seeming 'no-brainer' opportunity by buying at $5 and change and letting go between $10-12. I'm not sure what to think at the moment.
Here's why it makes no sense to me:
The experts claim:
There are currently between 160K - 1.5M LN sufferers
The incidence rate of LN among SLE patients is between 50-60%
We know that the average cost to get an FDA approved drug takes years and costs $2B plus
There's a financial graveyard of LN drugs that have failed to succeed and have never made it out of the clinic.
Aurinia has probably spent $2B in total costs themselves over many years to achieve the best LN drug ever.
I find it very strange that the uptake for Lupkynis is truly pathetic as they have failed to gain any real sales traction for the best hope for patients with LN ever.
Curiouser and curiouser.
Despite the discouraging track record to date, I still can't resist continuing to nibble away on this.
Why would any Pharma take huge risks on their likely future failure LN candidate when they could simply buy this and use their marketing muscle to make it a winner?
cheers
Moose, kind of explains why Auphie made the oversold list of your previous post. Maybe PG sees the writing on the wall as far as his tenure goes.
Aurinia Pharmaceuticals President Peter Greenleaf Sells 29% Of Holding
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-auph/aurinia-pharmaceuticals/news/aurinia-pharmaceuticals-president-peter-greenleaf-sells-29-o
Really surprising that this is here now:
https://stocktwits.com/Big_Red2/message/566327711
11 Oversold Biotech Stocks To Buy Right Now
AUPH is #7
https://finance.yahoo.com/news/11-oversold-biotech-stocks-buy-212004324.html
Pretty sure the date has not yet been set nor announced.
When and where is this month's annual meeting of shareholders?
Well, with that answer, I change my assumption to desperation…..😁
Zzaatt sounds nervous…
Oh my God! What happened???
Did a patient die?? Did they discover an unknown toxicity?? Is the company running out of money?? NOPE! None of the above. We missed "estimates" by a few pennies. My feeling is the "estimators" had no clue and the company will continue to chug along and as it start showing a profit, either the PPS will go up, or there will be buyout. Not to worry.
I second that Amen Newbie
Amen Newbie. The posts are all about PG being a pig for receiving big salary and not selling the company, nothing else in 2/3 years.
So, Ive read all of your posts the last couple of years. Approximately 75-100 of them. All related to shareholder value and PG. Never once mentioning patients. Until now and your supposed dialysis. I know a rat when I see one.
Cervelo Sorry to hear you spent a year on dialysis and glad to hear you recovered kidney function .
Can U share what caused your loss of kidney function and what meds you are on now. ?
A good friend of mine had a coronary bypass and the contrast used crashed his kidneys . Resulted in him being on dialysis and in the ICU for 10 days .
Good luck
Kiwi
well newbie since you asked
and while you are showing your ignorance and stupidity.
I am married to a nurse and I spent a year on dialysis trying to get my kidneys functioning again.
So yes I care about the drug and especially those who need it, dialysis is no way of life it consumes all that you do, 3 days a week for hours the recover on the days off.
go back and read months ago petes goals...shareholder value and get the drug to more people that need it.
at that time we were just above 12.00 dollars now we sit at less than half of that.
the quarterly financials are barely moving upwards, thus showing pete is not promoting and getting the drug to more patients.
So next time you think you know it all, put your foot in your mouth before you speak so you do not show the world your nescience.
remember the same fool that vote for petie vote for biden
Cervelo - stop pretending you give a damn about the patients
cosa the common sense answer
what is the plan? so it has been nothing except enriching pete
someone said relax nothing has changed... that is the problem nothing has changed. in 5 years of pete we now sit with a share price a dollar less than when he took over.
The company will only move forward and have a pps rise when something does change.
the market does not like pete and has zero faith in him unlike those who praise him.
pete obviously is here to gia feeling he can continue to milk the company bank account.
so when the vote comes up go ahead like many will do and vote your own doom and cast a vote for pete
ask why some funds are clearing out their holdings in auph
if we are fortunate we may see upwards of 20.00 but it will take another 5 years at which time the corner on the market will be running out.
the sales are not increasing to the point where they can keep the company afloat so pete will continue to suck off the savings with future dilution.
back to quiet mode. just wanted to step in since no one is willing to see the facts as they really are.
all things being equal the share price should have never gone below where it hit because of fda approval.
BMY would have been a excellent bo partner and the drug would be getting to more patients need it.
Cosa, you pose an excellent question and it is surprising that it hasn’t received more attention and discussion here. There are obviously cases where a share buyback makes sense, but not usually when you are a small company attempting to launch and grow a drug - your only drug.
I have to assume that these initiatives have some end goal which was not divulged to us but possibly became clear to management thru the SR.
Not a fan of the buy back or ending the R&D. Doesn't make sense to me. Have less money and nothing in the pipeline. What is their plan?....
Thank you for the reply!
Newbie, just the only thing different is the fact that they are suspending their development of the other stuff, the payroll cutback and the buyback. Lupy is still a mile ahead of the other fading competitors and clearly backed up by EULAR and KDIGO’s position. In my humble opinion, PG knows his tenure is not unlimited and as such he may surprise us suffering investors between now and ASM…jmo.
Jesspro....Where are you??
I need your optimism right about now.
You do have a limitless amount of BS to offer!
(it helps that none of your "opinions" and "predictions" have any content)
Candidate & Indication | Development Stage | ||||
---|---|---|---|---|---|
Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |
VOCLOSPORINLupus Nephritis (LN) | Preclinical Phase complete | Phase 1 Phase complete | Phase 2 Phase in progress | Phase 3 Phase not started | Market Phase not started |
Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).
Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.
Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.
Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:
In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.
The list of potential product benefits includes:
LN Critical Need | Voclosporin (based on AURA Results) | |
---|---|---|
Control of Active Disease | ||
Rapid Disease Control | ||
Lower Steroid Burden | ||
Impact on Extra-renal disease | ||
Convenient Treatment Regimen |
In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s
Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.
No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |